Everest Medicines' Licensing Partner NovaBridge and Visara Announce Positive Results from VIS-101 Phase 2a Wet AMD Study
NovaBridge Biosciences - American Depositary Shares (NBP)
Company Research
Source: PR Newswire
VIS-101, purpose-designed to be best-in-class for retinal vascular diseases, is a tetravalent, dual VEGF-A X ANG-2 inhibitorTopline Phase 2a data show VIS-101 provides rapid, robust and durable treatment responses in wet AMDVIS-101 demonstrated mean BVCA improvements of 10 ETDRS letters and median CST reductions of 100-150 mmPotentially best-in-class durability with a favorable safety profile and no dose-limiting toxicityPhase 2b dose-determining study expected to begin in H2 2026; global Phase 3 program expected to begin in 2027SHANGHAI, March 13, 2026 /PRNewswire/ -- Everest Medicines (HKEX: 1952.HK) today announced that its licensing partner, NovaBridge Biopharma (NASDAQ: NBP, "NovaBridge"), together with its subsidiary Visara, Inc. ("Visara"), reported positive topline results from the Phase 2a study of VIS-101, a purpose-designed tetravalent, dual VEGF-A X ANG-2 inhibitor in development for retinal vascular diseases including wet age-related macular degeneration (wet AMD), diabet
Show less
Read more
Impact Snapshot
Event Time:
NBP
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
NBP alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
NBP alerts
High impacting NovaBridge Biosciences - American Depositary Shares news events
Weekly update
A roundup of the hottest topics
NBP
News
- I-Mab (NBP) had its "buy" rating reaffirmed by HC Wainwright. They now have a $9.00 price target on the stock.MarketBeat
- NovaBridge Announces Productive FDA Type B Meeting on Potential Accelerated Approval Pathway for Givastomig in Gastric Cancer [Yahoo! Finance]Yahoo! Finance
- NovaBridge Announces Productive FDA Type B Meeting on Potential Accelerated Approval Pathway for Givastomig in Gastric CancerGlobeNewswire
- NovaBridge Biosciences (NBP) Discusses Phase 2a Clinical Data and Development Plan for VIS-101 in Wet Age-Related Macular Degeneration Transcript [Seeking Alpha]Seeking Alpha
- NovaBridge and Visara Announce Positive Results from VIS-101 Phase 2a Wet AMD Study [Yahoo! Finance]Yahoo! Finance
NBP
Sec Filings
- 3/16/26 - Form 6-K
- 3/9/26 - Form 6-K
- 3/3/26 - Form 6-K
- NBP's page on the SEC website